This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.70% per year. These returns cover a period from January 1, 1988 through April 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
Zacks News
Masimo (MASI) Beats on Q3 Earnings and Revenues, Raises View
by Zacks Equity Research
Masimo (MASI) raises fiscal 2017 guidance. The year-over-year increase in both revenues and earnings encourages.
Abiomed (ABMD) Looks Good: Stock Adds 7.5% in Session
by Zacks Equity Research
Abiomed (ABMD) was a big mover last session, as the company saw its shares rise more than 7% on the day amid huge volumes.
Luminex (LMNX) Tops Q3 Earnings, Meets Revenue Estimates
by Zacks Equity Research
Luminex's (LMNX) third quarter saw a strong top line, solid cash flow as well as profits in Q3. The company's Assay business is likely to drive growth over the long term.
Express Scripts (ESRX) Q3 Earnings In Line, FY17 View Up
by Zacks Equity Research
Express Scripts Holding Company (ESRX) posted robust first-quarter numbers driven by operational cost improvement backed by focus on technology, digital tools, home delivery and specialty services.
Intuitive Surgical (ISRG) Beats on Q3 Earnings & Revenues
by Zacks Equity Research
Intuitive Surgical (ISRG) posted solid numbers in the third quarter, courtesy of rising customer adoption of procedures and growth in system placements.
athenahealth (ATHN) Beats Earnings, Misses Revenues in Q3
by Zacks Equity Research
athenahealth (ATHN) witnessed a year-over-year increase in Q3 revenues on the back of strength in its Business and Services segment.
Here's Why Investors Should Sell Patterson Companies Now
by Zacks Equity Research
Rapidly changing healthcare environment in the United States, unfavorable price movement, a competitive dental products distribution industry and integration risks pose significant challenges for Patterson Companies (PDCO).
Here's Why Investors Should Sell Ecolab (ECL) Right Away
by Zacks Equity Research
Intensifying competition, foreign exchange volatility, higher raw material costs and integration risks are primary headwinds for Ecolab (ECL) as of now.
OPKO Health (OPK) Signs New Agreement with Japan Tobacco
by Zacks Equity Research
OPKO Health's (OPK) new agreement with Japan Tobacco will enhance prospects of its kidney drug RAYALDEE in Japan.
Ecolab (ECL) to Divest Equipment Care Segment, Shares Fall
by Zacks Equity Research
In August, management at Ecolab (ECL) announced that equipment care business has been witnessing a quiet period, registering just 2% growth on a year-over-year basis in the last quarter.